The diabetes medicine sales in Denmark were recorded at USD 41.56 per capita in 2023. The forecast data from 2024 to 2028 shows a steady increase: 42.6 in 2024, 43.77 in 2025, 44.91 in 2026, 46.03 in 2027, and 47.13 in 2028. The year-on-year percentage variation highlights a consistent growth trend, demonstrating a rising demand and investment in diabetes medication. Over the last two years, the increases were 2.93% from 2023 to 2024 and 2.75% from 2024 to 2025.
Future trends to watch for include potential advancements in treatment options, increased prevalence of diabetes, and the impact of healthcare policies aimed at managing the condition more effectively. The compound annual growth rate (CAGR) over the next five years indicates an average annual growth of 2.53%, suggesting a stable upward trend in sales.
